Application of genomics, proteomics and metabolomics in drug discovery, development and clinic

Therapeutic Delivery

Volumn 4, Issue 3, 2013, Pages 395-413

  Russell, Craig ^a   Rahman, Ayesha ^a   Mohammed, Afzal R ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA FRAGMENT;

ARTICLE; CLINICAL PRACTICE; DNA HYBRIDIZATION; DNA METHYLATION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG RESPONSE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLIC DISORDER; METABOLOMICS; MOLECULAR SIZE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ONLINE SYSTEM; PHAGE DISPLAY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN MICROARRAY; PROTEOMICS; SEPARATION TECHNIQUE; SEQUENCE ANALYSIS; TOXICOGENETICS; TWO HYBRID SYSTEM;

EID: 84874588078     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.4     Document Type: Article

References (97)

1. Burbaum J, Tobal GM. Proteomics in drug discovery. Curr. Opin. Chem. Biol. 6, 427-433 (2002).
2. Butchdanger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104 (1996).
3. Apic G, Ignjatovic T, Boyer S, Russell RB. Illuminating drug discovery with biological pathways. FEBS Lett. 579, 1872-1877 (2005).
4. Shah T, de Villiers E, Nene V et al. Using the transcriptome to annotage the genome revisited: application of massively parallel signature sequencing (MPSS). Gene 336, 104-108 (2006).
5. Bentley DR. Whole-genome re-sequencing. Curr. Opin. Gen. Dev. 16, 545-552 (2006).
6. Tawfik DS, Griffiths AD. Man-made cell-like compartments for molecular evolution. Nat. Biotechnol. 16, 652-656 (1997).
7. Morozova O, Marra MA. Applications of next-generation sequencing technologies in functional genomics. Genomics 92, 255-264 (2008).
8. Guo L, Liang T, Lu Z. A comprehensive study of multiple mapping and feature selection for correction strategy in the analysis of small RNAs from SOLiD sequencing. Biosystems 104, 87-93 (2011).
9. Rothberg JM, Hinz W, Rearick TM et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 475, 348-352 (2011).
10. Eid J, Fehr A, Gray J et al. Real-time DNA sequencing from single polymerase molecules. Science 323, 133-138 (2009).
11. Milward EA, Daneshi N, Johnstone DM. Emerging real-time technologies in molecular medicine and the evolution of integrated 'pharmacomics' approaches to personalized medicine and drug discovery. Pharmacol. Ther. 136, 295-304 (2012).
12. McGinn S, Gut IG. DNA sequencing-spanning the generations. N. Biotechnol. S1871-S6784(12), 00869-2 (2012).
13. Clarke J, Wu HC, Jayasinghe L, Patel A, Reid S, Bayley H. Continuous base identification for single-molecule nanopore DNA sequencing. Nat. Nanotechnol. 4(4), 265-270 (2009).
14. Derrington IM, Butler TZ, Collins MD et al. Nanopore DNA sequencing with MspA. Proc. Natl Acad. Sci. USA 107(37), 16060-16065 (2010).
15. Wu HC, Astier Y, Maglia G, Mikhailova E, Bayley H. Protein nanopores with covalently attached molecular adapters. J. Am. Chem. Soc. 129(51) 16142-16148 (2007).
16. Garaj S, Hubbard A, Reina A, Kong J, Branton D, Golovchenko JA. Graphene as a subnanometre trans-electrode membrane. Nature 467, 190-193 (2010).
17. Augenlicht LH, Kobrin D. Cloning and screening of sequences expressed in a mouse colon tumor. Cancer Res. 42(3), 1088-1093 (1982).
18. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270(5235), 467-470 (1995).
19. Lashkari DA, DeRisi JL, McCusker JH et al. Yeast microarrays for genome wide parallel genetic and gene expression analysis. Proc. Natl Acad. Sci. USA 94(24), 13057-13062 (1997).
20. Karakach TK, Flight RM, Douglas SE, Wentzell PD. An introduction to DNA microarrays for gene expression analysis. Chemometr. Intell. Lab. 104, 28-52 (2010).
21. Li X, Qi X, Miao L et al. Detection and subtyping of influenza A virus based on a short oligonucleotide microarray. Diagn. Microbiol. Infect. Dis. 65, 261-270 (2012).
22. Grover V, Pierce ML, Hoyt P, Zhang F, Melcher U. Oligonucleotide-based microarray for detection of plant viruses employing sequence-independent amplification of targets. J. Virol. Methods. 163, 57-67 (2010).
23. Zhao S, Recknor J, Lunney JK et al. Validation of a first-generation long-oligonucleotide microarray for transcriptional profiling in the pig. Genomics 86, 618-625 (2005).
24. Barrett JC, Kawasaki ES. Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression. Rev. Res. Focus 8(3), 134-141 (2003).
25. van den Boom D, Beaulieu M, Oeth P et al. MALDI-TOF MS: a platform technology for genetic discovery. Int. J. Mass Spectrom. 238, 173-188 (2004).
26. Lewin DA, Weiner MP. Molecular biomarkers in drug development. Drug Discov. Today 9(22), 976-983 (2004).
27. Meulenbelt I, Kraus VB, Sandell LJ, Loughlin J. Summary of the OA biomarkers workshop 2010-genetics and genomics: new targets in OA. Osteoarthr. Cartil. 19, 1091-1094 (2011).
28. Chengalvala MV, Chennathukuzhi VM, Johnston DS, Stevis PE, Kopf GS. Gene expression profiling and its practice in drug development. Curr. Genomics 8, 262-270 (2007).
29. Hernandez DG, Nalls MA, Moore M et al. Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol. Dis. 47, 20-28 (2012).
30. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59, 164-182 (2007).
31. Zhang J, Liu Q, Li Y, Hall SH, French FS, Zhang YL. Genome-wide profiling of segmental-regulated transcriptomes in human epididymis using oligo microarray. Mol. Cell. Endocrinol. 250, 169-177 (2006).
32. Yudate HT, Kai T, Aoki M et al. Identification of a novel set of biomarkers for evaluating phospholipidosis-inducing potential of compounds using rat liver microarray data measured 24 h after single dose administration. Toxicology 295, 1-7 (2012).
33. Knudson TB, Daston GP. MIAME guidelines. Reprod. Toxicol. 19, 263 (2005).
34. Einbond LS, Soffritti M, Esposti DD et al. Pharmacological mechanisms of clack cohosh in Sprague-Dawley rats. Fitoterapia 83, 461-468 (2012).
35. Hardiman G. Application of ultra-high throughput sequencing and microarray technologies in pharmacogenomics testing. In: Therapeutic Drug Monitoring: Newer Drugs and Biomarkers (Chapter 7). Dasgupta A (Ed.). Elsevier Science Publishing Co Inc., London, UK, 144-159 (2012).
36. Xu R, Wang Q. A knowledge-driven conditional approach to extract pharmacogenomics specific drug-gene relationships from free text. J. Biomed. Inform. 45(5), 827-834 (2012).
37. Li J, Lu Z. Systematic identification of pharmacogenomics information from clinical trials. J. Biomed. Inform. 45(5), 870-878 (2012).
38. Stone A, Bornhorst J. An introduction to personalized medicine. In: Therapeutic Drug Monitoring: Newer Drugs and Biomarkers (Chapter 6). Dasgupta A (Ed.). Elsevier Science Publishing Co Inc., London, UK, 122-142 (2012).
39. Sati S, Ghosh S, Jain V, Scaria V, Sengupta S. Genome-wide analysis reveals distinct patterns of epigenetic features in long non-coding RNA loci. Nucleic Acids Res. 40(20), 10018-31 (2012).
40. Huss M. Introduction into the analysis of high-throughput-sequencing based epigenome data. Brief. Bioinform. 11(5), 512-523 (2010).
41. Ohtsuki S, Schaefer O, Kawakami H et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP- glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 40(1), 83-92 (2012).
42. Sidoli S, Cheng L, Jensen ON. Proteomics in chromatin biology and epigenetics: elucidation of post-translational modifications of histone proteins by mass spectrometry. J. Proteomics 75, 3419-3433 (2012).
43. Cruz-Monteagudo M, Munteanu CR, Borges F, Cordeiro MN, Uriarte E, Gonzalez-Diaz H. Quantitative proteome-property relationships (QPPRs). Part 1: finding biomarkers of organic drugs with mean Markov connectivity indices of spiral networks of blood mass spectra. Bioorg. Med. Chem. 16, 9684-9693 (2008).
44. McDonald WH, Ohi R, Miyamoto DT, Mitchison TJ, Yates JR. Comparison of three directly coupled HPLC MS/MS strategies for identification of proteins from complex mixtures: single-dimension LC-MS/MS, 2-phase MudPIT, and 3-phase MudPIT. Int. J. Mass Spectrom. 219, 245-251 (2002).
45. Yang Z, Chevolot Y, Ataman-Onal Y, Choquet-Kastylevsky G, Souteyrand E, Laurenceau E. Cancer biomarkers detection using 3D microstructured protein chip: implementation of customized multiplex immunoassay. Sens Actuators B Chem. 175, 22-28 (2011).
46. Tunon J, Martin-Ventura JL, Blanco-Colio LM, Lorenzo O, Lopez JA, Egido J. Proteomic strategies in the search of new biomarkers in atherothrombosis. J. Am. Coll. Cardiol. 55(19), 2009-2016 (2010).
47. Mann M. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol. 7(12), 952-958 (2006).
48. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3, 1154-1169 (2004).
49. Wiedl T, Arni S, Roschitzki B et al. Activity-based proteomics: identification of ABHD11 and ESD activities as potential biomarkers for human lung adenomacarconoma. J. Proteomics 74, 1884-1894 (2011).
50. Kim H, Kang U, Lee H et al. Profiling of differentially expressed proteins in stage IV colorectal cancers with good and poor outcomes. J. Proteomics 75, 2982-2997 (2011).
51. Park SS, Wu WW, Zhou Y et al. Effective correction of experimental errors in quantitative proteomics using stable isotope labeling by amino acids in cell culture (SILAC). J. Proteomics 75, 3720-3732, (2012).
52. Zhu W, Smith JW, Huang CM. Mass spectrometry-based label-free quantitative proteomics. J. Biomed. Biotechnol. 2010, 840518 (2010).
53. Kramer HB, Nicholson B, Kessler BM, Altun M. Detection of ubiquitin-proteasome enzymatic activities in cells: application of activity-based probes to inhibitor development. Biochim. Biophys. Acta 1823(11), 2029-2037 (2012).
54. Hall DA, Pyacek J, Snyder M. Protein microarray technology. Mech. Ageing. Dev. 128, 161-167 (2007).
55. Zhu H, Snyder M. Protein chip technology. Curr. Opin. Chem. Biol. 7, 55-63 (2003).
56. Sreekumar A, Nyati MK, Varambally S et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. 61, 7585-7593 (2001).
57. Hall DA, Zhu H, Zhu X et al. Regulation of gene expression by a metabolic enzyme. Science 306, 482-484 (2004).
58. Zhu H, Bilgin M, Bangham, R et al. Global analysis of protein activities using proteome chips. Science 293, 2101-2105 (2001).
59. Speer R, Wulfkuhle JD, Liotta LA, Petricoin EF 3rd. Reverse phase protein microarrays for tissue-based analysis. Curr. Opin. Mol. Ther. 7, 240-245 (2005).
60. Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC. Antibody phage display and its applications. Immunotechnology 4, 1-20 (1998).
61. Nam J, Stoeva SI, Mirkin CA. Bio-bar-code-based DNA detection with PCR-like sensitivity. J. Am. Chem. Soc. 126, 5932-5933 (2004).
62. He M, Taussig MJ. Ribosome display: cell-free protein display technology. Brief. Funct. Genomic. Proteomic. 1(2), 204-212 (2002).
63. Rothe A, Hosse RJ, Power BE. Ribosomal display for improved biotherapeutic molecules. Expert Opin. Biol. Ther. 6(2), 177-187 (2006).
64. Suter B, Kittanakom S, Stagljar I. Two-hybrid technologies in proteomics research. Curr. Opin. Biotechnol. 19, 316-323 (2008).
65. Fetchko M, Stagljar I. Application of the split-ubiquitin membrane yeast two-hybrid system to investigate membrane protein interactions. Methods 32, 349-362 (2004).
66. Luo Y, Batalao A, Zhou H, Zhu L. Mammalian two-hybrid system: a complementary approach to the yeast two-hybrid system. Biotechniques 22, 350-352 (1997).
67. Lange V, Picotti P, Domon B et al. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 4(222), 1-14 (2008).
68. Kell DB, Systems biology, metabolic modeling and metabolomics in drug discovery and development. Drug Discov. Today 11(23-24), 1085-1092 (2006).
69. D'Alessandro A, Zolla L, Metabolomics and cancer drug discovery: let the cells do the talking. Drug Discov. Today 17(1-2), 3-9 (2012).
70. Schauer N, Steinhauser D, Strelkov S et al. GC-MS libraries for the rapid identification of metabolites in complex biological samples. FEBS Lett. 579(6), 1332-1337 (2005).
71. Gika HG, Theodoridis GA, Wingate JE, Wilson ID. Within-day reproducibility of an LC-MS-based method for metabonomic analysis: application to human urine. J. Proteome Res. 6(8), 3291-3303 (2007).
72. Ramautar R, Somsen GW, de Jong GJ. CE-MS in metabolomics. Electrophoresis 30, 276-291 (2009).
73. Griffin JL. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterization of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol. 7(5), 648-654 (2003).
74. Smith C, O'Maille G, Want E et al. METLIN: a metabolite mass spectral database. Ther. Drug Monit. 27(6), 747-751 (2005).
75. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 32, D277-D280 (2004).
76. Smith CA, Maille GO, Want EJ et al. METLIN: a metabolite mass spectral database. Ther. Drug Monit. 27(6), 747-751 (2005).
77. Kanehisa M, Goro S, Hattori M et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 34, D354-D357 (2006).
78. Aloy P, Russell RB. Potential artefacts in protein-interaction networks. FEBS Lett. 530, 253-254 (2002).
79. von Mering C, Krause R, Snel B et al. Comparative assessment of large-scale data sets of protein-protein interactions. Nature 417, 399-403 (2002).
80. Sato T, Watanabe H, Tsuganezawa K et al. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures. Bioorg. Med. Chem. 20, 3756-3767 (2012).
81. Mardinoglu A, Nielsen J. Systems medicine and metabolic modeling. J. Int. Med. 271, 142-154 (2012).
82. Hawkins R, Hon G, Ren B. Next-generation genomics: an integrative approach. Nat. Rev. Genet. 11, 476-486 (2010).
83. Bruggeman J, Westerhoff HJ. The nature of systems biology. Trends Microbiol. 15(1), 45-50 (2006).
84. Vinayavekhin N, Homan E, Saghatelian A. Exploring disease through metabolomics. ACS Chem. Biol. 5(1), 91-103 (2010).
85. Qin XY, Wei F, Yoshinaga J, Yonemoto J, Tanokura M, Sone H. siRNA-mediated knockdown of aryl hydrocarbon receptor nuclear translocator 2 affects hypoxia-inducible factor-1 regulatory signaling and metabolism in human breast cancer cells. FEBS Lett. 585, 3310-3315 (2011).
86. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumor. Nat. Rev. Cancer 8, 705-713 (2008).
87. Griffiths JR, McSheehy PM, Robinson SP et al. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild type tumors and tumors deficient in hypoxia-inducible factor-1 beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. Cancer Res. 62, 688-695 (2002).
88. Duarte NC, Becker SA, Jamshidi N et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl Acad. Sci. USA 104, 1777-1782 (2007).
89. Hao T, Ma HW, Zhao XM, Goryanin I. Compartmentalization of the Edinburgh Human Metabolic Network. BMC Bioinformatics 11(393), 1-12 (2010).
90. Romero P, Wagg J, Green ML et al. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol. 6(1), R21-R217 (2005).
91. Agren R, Bordel S, Mardinoglu A, Pornputtapong N, Nookaew I, Nielsen J. Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput. Biol. 8(5), 1-9 (2012).
92. Gille C, Bolling C, Hoppe A et al. HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol. Syst. Biol. 6(441), 1-13 (2010).
93. Jerby L, Shlomi T, Ruppin E. Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol. Syst. Biol. 6(401), 1-9 (2010).
94. Chang RL, Xie L, Bourne PE, Palsson BO. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol. 6(9), e1000938 (2010).
95. Lewis NE, Schramm G, Bordbar A et al. Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol. 28, 1279-1285 (2010).
96. Bordbar A, Jamshidi N, Palsson BO. iAB-RBC-283: a proteomically derived knowledge-base of erythrocyte metabolism that can be used to simulate its physiological and patho-physiological states. BMC Syst. Biol. 5(110), 1-12 (2011).
97. Bordbar A, Lewis NE, Schellenberger J, Palsson BO, Jamshidi N. Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions. Mol. Syst. Biol. 6(422), 1-14 (2010).